Vincent Zucconi’s Post

💰 AbbVie has announced the acquisition of Aliada Therapeutics for $1.4 billion in cash, strengthening its position in neuroscience drug development. The deal centers on Aliada's novel blood-brain barrier (BBB)-crossing technology and its lead Alzheimer's disease candidate, ALIA-1758, a development particularly significant given that women represent nearly two-thirds of Americans living with Alzheimer's disease. 🔬 💬 "Neuroscience is one of our key growth areas and we are committed to driving innovation in this field to address critical unmet needs for patients living with seriously debilitating neurological diseases such as Alzheimer's disease. This acquisition immediately positions us to advance ALIA-1758, a potentially best-in-class disease-modifying therapy for Alzheimer's disease." Roopal Thakkar, AbbVie Executive Vice President, Research and Development and Chief Scientific Officer #femtech #womenshealth #womenshealthinnovation #healthcare #healthcareinnovation #pharma #biotech #clinicaltrial #acquisition #alzheimers #brainhealth #healthyaging #drugdevelopment

Assessing drug-induced Central Nervous System (CNS) risks is crucial in developing effective therapeutics for this indication. Careful attention must be given to evaluating potential neurotoxic effects that a new drug may induce or exacerbate. Check out our blog, where Allucent experts Marcus Delatte, PhD, Alison Wakeford, PhD, Devin Welty, PhD, and Rachel (Tyson) Rozakis, PharmD, examine various approaches used in preclinical drug development to accurately assess CNS risk, as well as the challenges in conducting those assessments. Read the blog to learn more: https://lnkd.in/gBYnQcsq #Allucent #BringNewTherapiesToLight #CRO #ClinicalPharmacology #Toxicity #Neurology #ClinicalResearch

Key insights on risk assessment in the preclinical phase when developing CNS therapeutics.

Please check out this informative article on strategies for assessing and managing neurotoxic risks in CNS drug development.

Neuroimaging Is The Future of CNS Drug Development Inside Alto Neuroscience's Efforts to Revolutionize Clinical Trials https://buff.ly/4gfdyT9 Neurotechnology’s opportunity to make clinical research and treatment more effective and efficient for all parties remains largely unrealized across the pharmaceutical industry. Though many life sciences companies have placed early bets on digitization and decentralization, few have built their entire business model on leveraging novel brain health biomarkers in “owned” drug development. Enter Alto Neuroscience, a psychiatric pharma startup powered by neurotech R&D. Let’s start with a quick overview of what that entails, from their 2023 10-K: “Our Platform and differentiated approach aim to disrupt the trial-and-error method that is currently standard practice in CNS drug development and clinical care….Our Platform and approach employ modern tools for measuring human neurobiology together with rigorous data science analytics to discover, and prospectively replicate, biomarker responders, or patients that may demonstrate better clinical response to our novel product candidates. We believe this approach (can) increase the probability of clinical success by magnifying the impact of each product candidate, thereby yielding a differentiated drug profile.”

Herantis Pharma Plc. in the PharmaTimes, PharmaTimes Media Ltd, UK. Herantis’ chief executive officer, Antti Vuolanto, commented: “This external validation of Herantis’ science recognises the potential of HER-096 as a promising drug candidate for treatment of PD.” “Disease-modifying treatments that can meaningfully slow the progression of PD are a desperate unmet need for the millions living with this devastating condition,” explained Dr Arthur Roach, director of Parkinson’s Virtual Biotech, Parkinson's UK. #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology #PharmaTimes #ParkinsonsUK Read more https://lnkd.in/dSGchcWw

🧬 Neumora Therapeutics Raises $112M for Brain Disease Research TL;DR: • Total funding now at $650M • Two drugs in clinical trials • Strategic partnerships with Amgen & Arch Venture Partners • Novel approach: Precision targeting for patient subgroups Neumora Therapeutics continues to make waves in CNS drug development, securing an additional $112M in funding. This Massachusetts-based biotech powerhouse is revolutionizing how we approach brain diseases through precision medicine. Key Developments: • NMRA-140: Phase 2 trials for depression • NMRA-511: Phase 1 trials for anxiety disorders • New research program licensed from Vanderbilt University for schizophrenia treatment The company's unique strategy? Moving beyond broad diagnostic categories to develop targeted therapies for specific patient subgroups - a game-changer in CNS treatment. Phase 2 results for NMRA-140 expected by year-end. Watch this space. 💭 What are your thoughts on precision medicine in CNS drug development? Has your organization explored similar approaches? Share your insights below. #Biotech #Neuroscience #DrugDevelopment #PrecisionMedicine #BiotechInnovation #intelligencesimplified #pharma #biotech #biodatastudio

PsychoGenics offers comprehensive preclinical pharmacokinetic and pharmacodynamic services tailored for CNS drug development. Our integrated approach combines: ⚪ Specialized CNS-focused PK studies (including ICV administration) ⚪ Advanced bioanalysis (UPLC-MS/MS, MSD, Luminex) ⚪ Diverse PD endpoints: - Behavioral assays - EEG studies - Receptor occupancy - Microdialysis - Ex vivo biomarker analysis We provide critical data on: ✓ Brain penetration and CSF/plasma ratios ✓ Target engagement in CNS tissues ✓ PK/PD relationships in behavioral models Discover how our expertise can accelerate your neuroscience research!

"This first-in-human trial holds significant promise to investigate the ability of ANPD001 to improve the lives of people with moderate to advanced Parkinson's disease," said Edward Wirth III, MD, PhD, Chief Medical Officer of Aspen Neuroscience. "Our 2022 Trial Ready Cohort Screening Study has completed enrollment, and we plan to dose patients in the ASPIRO Phase 1/2a study this year." #DahliaConsulting #BiopharmaceuticalIndustry #CommercialLifeSciences #PMOStrategies #ManagementConsultant #LifeSciencesBusinessStrategy #GlobalPharma #GlobalBioTech #SupplychainOperations #CommercialOperations #CGTcommercialization #Manufacturing #QualityAssurance #OperationalExcellence #FinancialAnalysis #OpModelDesign #LifeScience #BioTechnology #Bioprocessing #StartupSuccess #CompliancewithPharma #OptimizingBusinessPerformance #Consulting #EfficientProjectDelivery #SuccessThroughPMO #PMO #ProjectManagementExcellence #PMOImplementation #Biosimilars #BioPharmaIndustry #BioPharmaceuticalConsulting #Pharmefex #Collaboration #PharmefexConsulting #MedicalResearch #CDMO #GMP #GMPbatch #GMPmanufacturing #GenomeEditing #GeneTherapy #CellTherapy #Car_T #mRNA #cGMP #ClinicalGradeManufacturing #ClinicalGradeProduction #BiologicsLicenseApplication #BLA #Pharma #Pharmaceuticals #RegenerativeMedicine #PNRNews #AspenNeuroscience #FirstInHuman #ClinicalTrial #AutologousNeuronalCellReplacementTherapy #ParkinsonsDisease #ANPD001

Therapeutic targeting of senescent cells in the CNS During aging process and in various disease conditions senescent cells accumulate and negatively impact health and function of multiple systems, including the central nervous system (CNS). Senotherapeutics to target senescent cells in CNS have been emerging and involve clearing senescent cells. Several senolytics like dasatinib and quercetin have emerged and have been used successfully in the preclinical studies although brain penetrance and potential toxic side efects of CNS-acting senotherapeutics pose challenges for drug development and translation to the clinic. This Review assesses the potential impact of senotherapeutics for neurological conditions by summarizing preclinical evidence, innovative methods for target and biomarker identifcation, academic and industry drug development pipelines and progress in clinical trials. #ScienceNewsHighlights #ScienceMission https://lnkd.in/ghqmmU-N https://lnkd.in/grdsS5-B